FFAR2 and metabolic dysfunction-associated steatotic liver disease: To investigate the impact of GPR43 downregulation on the therapeutic efficacy of APs-CS/PT-NPs in HCC, we administered sh-NC and sh-GPR43 lentiviruses via tail vein injection before establishing the NAFLD-HCC mouse model.